Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 13;13(6):1462.
doi: 10.3390/biomedicines13061462.

Heart Failure and Wide QRS: Clinical and Pharmacological Perspectives

Alfredo Mauriello  1 , Adriana Correra  2 , Gerardo Elia Del Vecchio  3 , Martina Grieco  4 , Arianna Amata  5 , Pierpaolo Di Micco  6 , Egidio Imbalzano  7 , Mariano Paternoster  8 , Antonia Ascrizzi  9 , Vincenzo Quagliariello  1 , Nicola Maurea  1 , Francesco Giallauria  10 , Antonello D'Andrea  11 , Vincenzo Russo  9
Affiliations
Review

Heart Failure and Wide QRS: Clinical and Pharmacological Perspectives

Alfredo Mauriello et al. Biomedicines. .

Abstract

Heart failure (HF) is a highly prevalent cardiovascular clinical syndrome. Health care spending on HF treatment is high. Therefore, its treatment has generated a great deal of interest in pharmacological research in recent years. Recent guidelines have introduced several molecules for the treatment of HF that have demonstrated safety, and above all, efficacy. One of the worst aspects of HF is ventricular dyssynchrony (VD) with a wide QRS interval. Currently, the cornerstone of VD therapy is cardiac resynchronization therapy (CRT). Our comprehensive review aims to analyze the effects of new molecules on QRS width and understand whether these molecules can provide benefits.

Keywords: QRS widening; cardiac remodeling; dapagliflozin; empagliflozin; heart failure; sacubitril/valsartan; ventricular dyssynchrony; vericiguat.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The five pillars of therapy for the pharmacological treatment of chronic heart failure. ACEi: angiotensin-converting enzyme inhibitors; ARBs: angiotensin-receptor blockers; ARNI: angiotensin receptor neprilysin inhibitor; MRA: mineralocorticoid receptor antagonist; SGLT2i: sodium glucose co-transporter 2 inhibitors.
Figure 2
Figure 2
Pathophysiology of intraventricular conduction delay in heart failure. ANS: autonomic nervous system; HF: heart failure; LV: left ventricle; MR: mitral regurgitation; RV: right ventricle; ↑: increase; ↓: decrease.
See this image and copyright information in PMC

References

    1. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., Čelutkienė J., Chioncel O., et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the Special Contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2021;42:3599–3726. doi: 10.1093/eurheartj/ehab368. Erratum in Eur. Heart J. 2021, 42, 4901. - DOI - PubMed
    1. Mauriello A., Ascrizzi A., Roma A.S., Molinari R., Caturano A., Imbalzano E., D’Andrea A., Russo V. Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives. Antioxidants. 2024;13:806. doi: 10.3390/antiox13070806. - DOI - PMC - PubMed
    1. Shahim B., Kapelios C.J., Savarese G., Lund L.H. Global Public Health Burden of Heart Failure: An Updated Review. Card. Fail. Rev. 2023;9:e11. doi: 10.15420/cfr.2023.05. - DOI - PMC - PubMed
    1. Kass D.A. Ventricular Dyssynchrony and Mechanisms of Resynchronization Therapy. Eur. Heart J. Suppl. 2002;4:D23–D30. doi: 10.1093/ehjsupp/4.suppl_D.D23. - DOI
    1. Hawkins N.M., Petrie M.C., MacDonald M.R., Hogg K.J., McMurray J.J.V. Selecting Patients for Cardiac Resynchronization Therapy: Electrical or Mechanical Dyssynchrony? Eur. Heart J. 2006;27:1270–1281. doi: 10.1093/eurheartj/ehi826. - DOI - PubMed

LinkOut - more resources